The U.S. Food and Drug Administration approved a new non-opioid pain medication developed by the Massachusetts-based company ...

Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...

Vertex Pharmaceuticals (VRTX) closed the most recent trading day at $440.68, moving -0.72% from the previous trading session. This change lagged the S&P 500's daily gain of 0.92%. Meanwhile ...

Analysts project ongoing solid performance from the CF business. BMO Capital Markets estimates Vertex will generate revenues of $11,573 million in 2025, with earnings per share reaching $18.05 ...

The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...

Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 11.2% of Oncternal Therapeutics shares are owned by company insiders. Comparatively, 0.2% of Vertex ...

Vertex Pharmaceuticals (VRTX) closed at $428 in the latest trading session, marking a +0.03% move from the prior day. The stock's change was less than the S&P 500's daily gain of 0.61%.

The rule will apply only to Brown’s Rhode Island facilities, including Rhode Island Hospital, Hasbro Children’s Hospital and Newport Hospital. Brown acquired St. Anne’s and Morton in 2024 ...